273 related articles for article (PubMed ID: 22019868)
1. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
4. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
Zara G; Zambello R; Ermani M
Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
6. [A case of IgM paraproteinemic neuropathy associated with anti-sulfated glucuronic paragloboside (SGPG) IgG antibody without anti-myelin-associated glycoprotein (MAG) activity].
Nakamura H; Endo M; Sugawara E; Kuwahara M; Kusunoki S; Tanaka F; Takahashi T
Rinsho Shinkeigaku; 2013; 53(10):799-802. PubMed ID: 24225562
[TBL] [Abstract][Full Text] [Related]
7. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia.
Weiss MD; Dalakas MC; Lauter CJ; Willison HJ; Quarles RH
J Neuroimmunol; 1999 Mar; 95(1-2):174-84. PubMed ID: 10229128
[TBL] [Abstract][Full Text] [Related]
8. [Polyneuropathy involving cranial nerves associated with monoclonal IgM antibodies with anti-MAG/SGPG/SGPLG/sulfatides activity].
Drouet A; Caudie C; Vallat JM; Ruel JH; Felten D; Guilloton L; Giraud P
Rev Neurol (Paris); 2006 Jun; 162(6-7):760-6. PubMed ID: 16840988
[TBL] [Abstract][Full Text] [Related]
9. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
11. Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy.
Tagawa Y; Yuki N; Hirata K
Muscle Nerve; 2000 Jun; 23(6):895-9. PubMed ID: 10842265
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.
Vallat JM; Magy L; Ciron J; Corcia P; Le Masson G; Mathis S
Expert Rev Neurother; 2016 Sep; 16(9):1111-9. PubMed ID: 27267749
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients.
Garces-Sanchez M; Dyck PJ; Kyle RA; Zeldenrust S; Wu Y; Ladha SS; Klein CJ
Muscle Nerve; 2008 Apr; 37(4):490-5. PubMed ID: 18236455
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD002827. PubMed ID: 27701752
[TBL] [Abstract][Full Text] [Related]
15. Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody.
Rech J; Hueber AJ; Kallert S; Leipe J; Kalden JR; Beck M; Schett G; Schulze-Koops H
Ther Apher Dial; 2008 Jun; 12(3):205-8. PubMed ID: 18503697
[TBL] [Abstract][Full Text] [Related]
16. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy.
Sala E; Robert-Varvat F; Paul S; Camdessanché JP; Antoine JC
J Neurol Sci; 2014 Oct; 345(1-2):224-7. PubMed ID: 25115501
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
18. NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy.
Benedetti L; Facco M; Franciotta D; Dalla Torre C; Campagnolo M; Lucchetta M; Boscaro E; Ermani M; Del Sette M; Berno T; Candiotto L; Zambello R; Briani C
J Neurol Sci; 2013 Aug; 331(1-2):86-9. PubMed ID: 23764364
[TBL] [Abstract][Full Text] [Related]
19. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment.
Campagnolo M; Ferrari S; Dalla Torre C; Cabrini I; Cacciavillani M; Lucchetta M; Ruggero S; Toffanin E; Cavallaro T; Briani C
J Neuroimmunol; 2015 Apr; 281():1-4. PubMed ID: 25867460
[TBL] [Abstract][Full Text] [Related]
20. High-dose rituximab and anti-MAG-associated polyneuropathy.
Renaud S; Fuhr P; Gregor M; Schweikert K; Lorenz D; Daniels C; Deuschl G; Gratwohl A; Steck AJ
Neurology; 2006 Mar; 66(5):742-4. PubMed ID: 16534115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
